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Background: To mimic clinical treatment situations in advanced human ovarian disease, we tested the efficacy of
CpG-oligodeoxynucleotides (CpG-ODN), synthetic DNA sequences recognized by Toll-like receptor 9 and able to
induce innate/adaptive immune responses, in combination with other possible therapeutic reagents in ovarian
carcinoma ascites-bearing athymic mice.
Methods: Mice injected i.p. with IGROV-1 ovarian cancer cells were treated at different stages of ascites progression
for 4 weeks with CpG-ODN, alone or in combination with Bevacizumab, Polyinosinic:Polycytidylic acid (Poly(I):
Poly(C)), Gefitinib, Cetuximab and Cisplatin. Median survival time (MST) was calculated for each group. IGROV-1 cells
treated or not with Cetuximab were assayed for antibody-dependent cellular cytotoxicity by 51Cr-release assay, and
for macrophage antibody-dependent cell-mediated phagocytosis by flow cytometry.
Results: In mice treated when ascitic fluid began to accumulate, CpG-ODN combined with Bevacizumab, Poly(I):
Poly(C) or Gefitinib did not significantly increase MST as compared with that using CpG-ODN alone, whereas MST in
mice treated with CpG-ODN plus Cetuximab was significantly increased (>103 days for combination vs 62 days for
CpG alone; P = 0.0008), with 4/8 mice alive at the end of the experiment. In experiments in mice showing increased
abdominal volume and body weight (27.9 ± 0.8 g after vs 23 ± 1.1 g before tumor cell injection), treatment with
Cisplatin in addition to CpG-ODN/Cetuximab led to significantly increased MST (105.5 days; P = 0.001), with all mice
still alive at 85 days, over that using CpG-ODN/Cetuximab (66 days), Cetuximab/Cisplatin (18.5 days), Cisplatin
(23 days) or saline (16 days). At a very advanced stage of disease (body weight: 31.4 ± 0.9 g), when more than half
of control mice had to be sacrificed 6 days after starting treatments, the triple-combination therapy still increased
MST (45 days; P = 0.0089) vs controls.
Conclusions: CpG-ODN combination therapies that enhance the immune response in the tumor
microenvironment and concomitantly target tumor cells are highly efficacious even in experimental advanced
malignancies. Although differences in the distribution of TLR9 in mice and humans and the enrichment of this
receptor on innate immune cells of athymic mice must be considered, our results indicate a promising strategy to
treat ovarian cancer patients with bulky ascites.
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Advanced tumor disease in humans is generally much
less responsive than limited disease to most anti-cancer
therapies. Testing of new cancer therapies in preclinical
models for advanced human ovarian cancer remains
rare. Treatment usually involves minimal disease and
therapy-naïve tumors, possibly accounting for the failure
to reproduce encouraging preclinical results in subse-
quent Phase I/Phase II clinical trials [1].
CpG-ODNs are synthetic DNA sequences that mimic
bacterial DNA and are recognized by the Toll-like recep-
tor 9 (TLR9) member of the TLR family as a “danger sig-
nal” [2,3] consisting of pathogen-associated molecular
patterns or stress-induced self molecules [4]. Interaction
of CpG-ODN with TLR9 can result in the generation of
both innate and adoptive immune responses, either of
which have the potential to significantly impact tumor
growth. CpG-ODN have demonstrated antitumor activ-
ity in different animal models [5,6] and in patients with
malignant melanoma, renal carcinoma and recurrent or
refractory lymphoma [7-10]. However, although both
preclinical and early clinical trials suggest the value of
CpG-ODN as a component of various approaches to
cancer therapy, clinical development of this recently dis-
covered novel class of immunostimulatory agents is in
the incipient stage and much remains unknown about
their optimal use [11]. Our recent studies revealed that
local, but not systemic, and daily, but not weekly, stimu-
lation of immune effector cells by CpG-ODN targeted
immunotherapy inhibited ascites production and signifi-
cantly prolonged survival in human ovarian carcinoma
ascites-bearing athymic mice [12]. However, CpG-ODN
monotherapy might be sufficient to induce tumor
regression only in small tumors; for larger tumors, CpG-
ODN needs to be combined with other effective anti-
tumor strategies [8]. Indeed, further evaluation in our
advanced-stage human ovarian tumor-bearing mouse
model showed that CpG-ODN combined with the
DNA-damaging chemotherapeutic drug cisplatin, which
is currently used in ovarian cancer patients [13], signifi-
cantly increased the lifespan of mice compared with the
individual treatments [14]. Interestingly, we found that
CpG-ODN treatment at the tumor site down-modulated
DNA repair genes in tumor cells [14]. The findings that
peri-tumoral delivery of CpG-ODN is critical in DNA
repair gene down-modulation in tumors but that CpG-
ODN does not interact directly with the tumor cells to
induce this down-modulation points to the importance
of the activation of TLR9-positive cells. Because CpG-
ODN-induced activation of TLR9-positive cells in the
tumor microenvironment might also induce increased
therapeutic activity of other drugs with different mechan-
isms of action, we used IGROV-1 ovarian carcinoma
ascites-bearing athymic mice to evaluate the efficacy ofCpG-ODN combined with: the monoclonal antibody
(MAb) Bevacizumab targeting the vascular endothelial
growth factor (VEGF) [15,16], which is reportedly overex-
pressed in ovarian cancer [17-19] and which regulates
angiogenesis as an important component of ovarian
cancer growth [16,20]; Poly(I):Poly(C), a TLR3 agonist
reported to synergize with TLR9 ligand to mediate
enhanced activation of innate immunity [21]; MAb
Cetuximab, which targets the ligand-binding domain
of the epidermal growth factor receptor (EGFR) fre-
quently expressed in ovarian cancer cells [20]; and
Gefitinib, a tyrosine kinase inhibitor of EGFR. Our ob-
servation that CpG-ODN plus Cetuximab strongly
increases survival over that seen with either reagent
alone led to analysis of the efficacy of a therapeutic
protocol involving CpG-ODN, Cetuximab and Cis-
platin in mice with very advanced ovarian tumors.
Materials and methods
Mice
Eight- to 12-week-old female Swiss nude (athymic) mice
(Charles River, Calco, Italy) were maintained in laminar-
flow rooms at constant temperature and humidity, with
food and water given ad libitum. Experiments were
approved by the Ethics Committee for Animal Experi-
mentation of the Fondazione IRCCS Istituto Nazionale
Tumori of Milan according to institutional guidelines.
ODNs and drugs
Purified, phosphorothioated ODN1826 (5’-TCCATGA
CGTTCCTGACGTT-3’) containing CpG motifs was
synthesized by TriLink Biotechnologies (San Diego, CA,
USA). Phosphorothioate modification was used to reduce
susceptibility of the ODN to DNase digestion, thereby sig-
nificantly prolonging its in vivo half-life. The following
drugs were used: Bevacizumab (Roche, Basel, Switzerland);
Poly(I)Poly(C) (Amersham Biosciences, Piscataway, NJ,
USA); Cetuximab (ErbituxW, Merck Serono, Darmstadt,
Germany); Gefitinib (LC Laboratories, Woburn, MA,
USA); and Cisplatin (Teva Italia, Milan, Italy). Lyophilized
ODN1826 and Poly(I):Poly(C) were dissolved in sterile
water at a concentration of 10 mg/ml and 2 mg/ml,
respectively, and stored at −20°C until use. Gefitinib was
dissolved in DMSO (10% v/v final concentration) and
diluted in carboxymethylcellulose (0.25% w/v) to a final
concentration of 10 mg/ml. Bevacizumab, Cetuximab and
Cisplatin (purchased in their commercial formulation)
were diluted in 200 μl of sterile saline at the indicated con-
centrations just before administration.
Cell culture
For in vitro experiments, human IGROV-1 ovarian
tumor cells (gift from Dr. J. Benard, Institute Gustave
Roussy, Villejuif, France) [22] were cultured in RPMI
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St. Louis, MO) and 2 mM glutamine (Cambrex, East
Rutherford, NJ, USA) (complete medium). Mouse leukemic
monocyte/macrophage RAW 264.7 cells (American Type
Culture Collection) were cultured in DMEM (Sigma) sup-
plemented with 10% FCS (Sigma) and 2 mM glutamine
(Cambrex). All cultures were maintained at 37°C in a 5%
CO2 humidified environment.Ev
en
ts
 Therapy studies
IGROV-1 human ovarian carcinoma cells were adapted
to growth i.p. and maintained by serial i.p. passages of
ascitic cells into healthy mice as described [22]. Mice
were injected i.p. with 2.5 × 106 ascitic cells in 0.2 ml of
saline and treated 7 days later, when ascitic fluid began
to accumulate, with CpG-ODN i.p. daily for 4 weeks (20 μg/
mouse) in combination with: Bevacizumab (5 mg/kg i.p. at
3–4 day intervals); Poly(I):Poly(C) (20 μg/mouse i.p. at
2–3 day intervals); Gefitinib (100 mg/kg per os, 5 days/
week); or Cetuximab (1 mg/mouse i.p. at 3–4 day
intervals). Single agents were also included and control
mice received saline.
In other experiments, mice with evident and estab-
lished ascites were selected on the basis of a similar body
weight (mean 27.9 ± 0.84 g, 31.4 ± 0.9 g, first and second
experiment, respectively) from large groups of mice
injected i.p. 11–12 days before IGROV-1 cell injection
and randomly divided into saline-treated (controls) and
groups treated with CpG-ODN, Cetuximab (both with
the schedules reported above) and Cisplatin (3 mg/Kg i.p.,
once weekly for 4 weeks) or their combinations. Experi-
mental groups (5–12 mice/group) were inspected daily for
ascites formation and weighed three times weekly. Mice
were individually sacrificed by cervical dislocation prior to
impending death. Day of sacrifice was considered day of
death, and the median day of death (median survival time;
MST) was calculated for each group. Anti-tumor activity
was assessed as the ratio of MST in treated vs. control
mice × 100 (T/C%).FL-1 
Figure 1 EGFR expression in IGROV-1 cells. Expression of EGFR in
IGROV-1 cells evaluated by FACS. Thin and bold lines represent
Alexa Fluor 488-secondary antibody and Cetuximab, respectively.Flow cytometry
IGROV-1 cells were exposed to Cetuximab (5 μg/m) for
72 h or left untreated, collected and incubated for
30 min at 4°C with anti-MICA, -MICB, -ULBP1,
-ULBP2, ULBP4, -CD112, -CD155, -ICAM-1, and HLA-E
antibodies (R&D Systems; Minneapolis, MN. USA), fol-
lowed by incubation with anti-mouse Alexa Fluor 448-
conjugated reagent (Invitrogen). Samples were analyzed
by gating on live cells using FACSCanto II system
(Becton-Dickinson, San Jose, CA) and BD FACSDiva™
software (Becton-Dickinson). EGFR expression levels
on IGROV-1 cells were determined after incubation
for 30 min at 4°C with Cetuximab (10 μg/ml), followedby incubation with anti-mouse Alexa Fluor 448-conjugated
antibody (Invitrogen).
Antibody-dependent cellular cytotoxicity (ADCC) assay
IGROV-1 cells were treated or not (controls) with Cetuxi-
mab (5 μg/ml for 72 h) and labeled with 100 μCi 51Cr
(PerkinElmer, Waltham, Massachusetts) for 1 h at 37°C.
After 3 washes with PBS-5% FCS, cells were co-incubated
for 4 h at 37°C with PBMC from 12 healthy donors (ef-
fector:target ratio 50:1) in 200 μl RPMI 1640 complete
medium in triplicate 96-well U-bottomed plates in the
presence of saturating concentrations of Cetuximab
(10 μg/ml). Radioactivity of the supernatant (80 μl) was
measured with a Trilux Beta Scintillation Counter (Perki-
nElmer). Percent specific lysis was calculated as: 100 ×
(experimental cpm - spontaneous cpm)/ (maximum
cpm - spontaneous cpm).
Phagocytosis assay
Macrophage antibody-dependent cell-mediated phago-
cytosis (ADCP) was assessed by flow cytometry [23].
Murine RAW264.7 effector cells were labeled with
PKH26 (Red Fluorescent Cell Linker Mini Kit), while
IGROV-1 target cells were labeled with PKH67 (Green
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ufacturer’s instructions (Sigma). IGROV-1 cells were
then seeded in tissue culture flasks and exposed to
Cetuximab (5 μg/ml for 72 h) or left untreated. At the
end of treatment, target and effector cells were mixed at
E:T ratio of 3:1 in complete medium and incubated for
12 h at 37°C in overload conditions of monoclonal anti-
body (10 μg/ml). Cells were collected, washed, resus-
pended in cold Ca2+- and Mg2+-free Dulbecco’s PBS and
analyzed by flow cytometry (FACSCanto II, Becton-
Dickinson). Phagocytosis of IGROV-1 cells by RAW264.7
cells was evaluated in triplicate as percentage and intensity
of macrophages positive for green fluorescence in at least
three separate experiments.
Statistical analysis
Percent survivorship was estimated by the Kaplan-Meier
product limit method and compared with the log-rank
test.
Results and discussion
The efficacy of CpG-ODN in combination with Poly(I):
Poly(C), Bevacizumab, Cetuximab, or Gefitinib was eval-
uated in mice injected i.p. with IGROV-1 cells (which
express EGFR, Figure 1) and treated on day 7, whenFigure 2 Kaplan-Meier plot of percent survival over time among IGRO
injection, mice were treated i.p. with CpG-ODN (20 μg/mouse, 5 days/week
to 3-day intervals); Bevacizumab (5 mg/Kg at 3- to 4-day intervals); Gefitinib
day intervals). Single agents were also tested. Control mice received saline.ascitic fluid began to accumulate. Repeated i.p. CpG-
ODN treatments plus Poly(I):Poly(C) induced negligible
effects on MST (65 days, T/C% 325) compared with
CpG-ODN treatment alone (61 days, T/C% 305), with 2
of 9 mice from the combined treatment group showing
long-term survival at the end of the experiment (120 days)
(Figure 2). The previously observed synergy between the
two immune modulators [21] was not seen, possibly due
to the schedule of CpG-ODN administration; indeed,
daily CpG-ODN administration might induce massive
innate cell activation hardly expandable by other im-
mune modulators.
Repeated i.p. CpG-ODN treatments plus anti-VEGF
Bevacizumab (Figure 2) also did not enhance the effect
of CpG-ODN treatment alone (MST 56 days for the
combination vs 62 days for CpG-ODN alone). Of note,
Bevacizumab as a single agent delayed the onset of asci-
tes (data not shown), consistent with recent preclinical
and clinical data and suggesting that targeting VEGF
might suspend ascites production resulting from peri-
toneal metastasis [24].
The combination of the EGFR tyrosine kinase inhibi-
tor Gefitinib and repeated i.p CpG-ODN induced only a
modest increase (p = 0.4099) in lifespan (MST 67 days,
T/C% 372) compared with that in mice treated withV-1 ovarian tumor-bearing mice. At 7 days after tumor cell
for 4 weeks) in combination with: Poly(I):Poly(C) (20 μg/mouse at 2-
(100 mg/mouse, 5 days/week) or Cetuximab (1 mg/mouse at 3- to 4-
N = number mice/group.
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survival was significantly increased (p = 0.0008) in mice
treated with CpG-ODN plus Cetuximab (MST > 103 days)
versus those treated with CpG-ODN alone (MST 62 days)
(Figure 2), with 4 of 8 mice still alive at the end of the
experiment. The latter finding most likely reflects CpG-
ODN-induced recruitment and activation of immune
effector cells at the site of tumor growth [25-27]; never-
theless these impressive results in a model in which the
antibody alone had slight effect might be also related to a
Cetuximab-induced increase in susceptibility of tumorC
A
F
D
B
G
Figure 3 Effect of Cetuximab pretreatment on phagocytosis of IGROV
lower quadrant) and RAW264.7 effector cells were stained red with PKH26
with 5 μg/ml Cetuximab (F,G,H) or left untreated (C,D,E). At the end of trea
ratio of 3:1 in complete medium and incubated for an additional 12 h in o
of double-positive cells present in the upper right quadrant (quadrant Q2)
phagocytosing green-stained tumor cells. Data were obtained in triplicatecells to CpG-ODN-activated effector cells involved in
ADCC and/or in phagocytosis [28,29].
Because HER signaling in tumors regulates expression
of MICA and MICB, key ligands that promote NK cell-
mediated recognition and cytolysis [30], and because
EGFR inhibitors enhance susceptibility to NK cell-
mediated lysis by modulating expression of the NKG2D
ligand ULBP-1 [30-32], we tested whether Cetuximab
treatment of IGROV-1 cells modulates expression of
molecules involved in NK-mediated lysis (MICA, MICB,
ULBP1, ULBP2, ULBP4, CD112, CD155, ICAM-1 andE
H 
-1 cells. IGROV-1 target cells were stained green with PKH67 (A, right
(B, left upper quadrant). Tumor targets were pre-incubated for 72 h
tment, target and effector cells were mixed at effector/target (E/T)
verload conditions of monoclonal antibody (10 μg/ml). The percentage
of the dot plots represents the percentage of RAW264.7 cells
and are representative of one of three experiments with similar results.
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Cetuximab (5 μg/ml) for 72 h revealed no significant effect
on expression of any these molecules (data not shown).
Moreover, 51Cr-release ADCC assay using Cetuximab-
pretreated or untreated IGROV-1 cell targets and PBMCFigure 4 Kaplan-Meier plot of percent survival over time in advanced
the presence of evident and established ascites from a large group of mice
SEM 27.89 ± 0.84 g vs 23.00 ± 1.08 g before tumor cell injection) were treat
mouse, 5 days/week for 4 weeks) plus Cetuximab (1 mg/mouse at 3- to 4-d
CpG-ODN plus Cetuximab and Cisplatin. (B) Mice selected for more advanced
before tumor cell injection) were treated with saline or CpG-ODN plus Cetuxifrom 12 healthy donors as effectors revealed no increase
in death percentage in the pretreated tumor cells (data not
shown). By contrast, in in vitro phagocytosis experiments
carried out in overload Cetuximab antibody conditions,
IGROV-1 cells pretreated with Cetuximab were more-stage IGROV-1 ovarian tumor-bearing mice. (A) Mice selected for
injected i.p. 11 days before with IGROV-1 cells (mean body weight ±
ed with saline, Cisplatin (3 mg/kg, once per week), CpG-ODN (20 μg/
ay intervals), CpG-ODN plus Cisplatin, Cetuximab plus Cisplatin, and
-stage disease (mean body weight ± SEM 31.4 ± 0.9 g vs 24.89 ± 0.68 g
mab and Cisplatin. N = number mice/group.
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(Figure 3) as compared to control cells. These findings
raise the possibility that Cetuximab also increases sus-
ceptibility to phagocytosis of tumor cells in vivo and
suggest that the strong anti-tumor activity observed in
the CpG-ODN/Cetuximab treatment might be due in
part to increased susceptibility to phagocytosis of
tumor cells induced by Cetuximab.
EGFR inhibitors reportedly also interact with Cisplatin
[33-36], although their effect on sensitivity to this drug
remains undefined. Based on our recent report of synergy
between CpG-ODN and Cisplatin [14], we investigated
the therapeutic effect of the combination of CpG-ODN,
Cetuximab and Cisplatin in mice selected for evident and
established ascites from a large group of mice injected i.p.
11 days before with IGROV-1 cells (mean body weight ±
SEM 27.9 ± 0.84 g vs 23.00 ± 1.08 g before tumor cell in-
jection; increased body weight = 4.9 g). Mice were ran-
domly divided into different groups and treated with
saline, Cisplatin, CpG-ODN plus Cetuximab, CpG-ODN
plus Cisplatin, Cetuximab plus Cisplatin, and CpG-ODN
plus Cetuximab and Cisplatin. Saline-, Cisplatin-, or
Cetuximab/Cisplatin-treated mice were euthanized on
days 13 to 36 after tumor cell injection (MST 16, 23 and
18.5 days, respectively), CpG-ODN/Cetuximab-treated
mice were euthanized between days 16–104 (MST 66 days;
T/C% = 412.5), while 7 mice treated with the triple com-
bination were euthanized on days 80–109, with 3 still alive
at the end of experiment. Thus, survival was significantly
increased (MST 105.5; T/C% 659.37; P = 0.001) compared
with CpG-ODN/Cetuximab-treated mice (Figure 4A).
Similar analysis in mice bearing even more advanced-
stage ascites (mean body weight ± SEM 31.4 ± 0.9 g vs
24.89 ± 0.68 g before tumor cell injection; increased body
weight = 6.51 g) showed that the CpG-ODN/Cetuximab/
Cisplatin combination still increased survival (MST 45;
T/C% 250, P = 0.0089 vs controls) (Figure 4B). Note
that 6 days after the start of treatment, 6 of 9 saline-
treated mice became moribund and were sacrificed.
Conclusions
Preclinical studies in which treatment is initiated only
after ascites is evident are rare and generally show a
small effect on survival. Our results indicate that com-
bination therapies to concomitantly enhance the im-
mune response in the tumor microenvironment and
target tumor cells can be effective even in advanced ma-
lignancies. Although differences in the distribution of
TLR9 receptors in mice and humans as well as the en-
richment of innate immune cells in athymic mice must
be considered, our findings point to a promising clinical
strategy for treating ovarian cancer patients with bulky
ascites. Thus, clinical trials of i.p. CpG-ODN treatment
in association with Cetuximab and Cisplatin might nowbe contemplated in ovarian carcinoma patients with
bulky disease.
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